First Trust NYSE Arca Biotechnology ETF

(fka First Trust AlphaDEX™ U.S. Materials Sector Index ETF)

Ticker: FBT

Quarter End Statement of Investments

1st Quarter as at March 31, 2024



| Sector Allocation | % of Net Asset Value |
|---|----------------------|
| Exchange-Traded Fund (First Trust NYSE® Arca® Biotechnology Index Fund ["Underlying Fund"])* Cash and Cash Equivalents | 99.98% 0.02% |
| Total Other Assets and Liabilities | 100.00% |
| Total Net Asset Value | 100.00% |

| Industry Allocation of the Underlying Fund | % of Net Asset Value of the Underlying Fund |
|--|--|
| Biotechnology | 74.39% |
| Life Sciences Tools & Services | 18.56% |
| Pharmaceuticals | 7.03% |
| Cash and Cash Equivalents | 0.10% |
| Total | 100.08% |
| Other Assets and Liabilities | (0.08%) |
| Total Net Asset Value of the Underlying F | und 100.00% |

| Country Allocation | % of Net Asset Value |
|------------------------|------------------------|
| of the Underlying Fund | of the Underlying Fund |
| United States | 87.25% |
| Netherlands | 3.48% |
| Ireland | 3.17% |
| Denmark | 3.13% |
| Cayman Islands | 2.95% |

| Holdings | % of Net Asset Value |
|--|----------------------|
| First Trust NYSE® Arca® Biotechnology Index Fund | 99.99% |
| Total Net Asset Value | \$1,830,500 |

| Top 25 Holdings of the Underlying Fund | % of Net Asset Value of the Underlying Fund |
|--|---|
| Natera, Inc. | 4.96% |
| Bruker Corporation | 4.36% |
| Halozyme Therapeutics, Inc. | 3.90% |
| Mettler-Toledo International, Inc. | 3.72% |
| Waters Corporation | 3.69% |
| Corcept Therapeutics, Incorporated | 3.59% |
| PTC Therapeutics, Inc. | 3.52% |
| Repligen Corporation | 3.51% |
| Argenx SE (ADR) | 3.48% |
| United Therapeutics Corporation | 3.46% |
| Exelixis, Inc. | 3.45% |
| Neurocrine Biosciences, Inc. | 3.45% |
| Intra-Cellular Therapies, Inc. | 3.44% |
| Regeneron Pharmaceuticals, Inc. | 3.41% |
| Exact Sciences Corp. | 3.40% |
| Moderna, Inc. | 3.32% |
| Illumina, Inc. | 3.29% |
| Vertex Pharmaceuticals, Incorporated | 3.19% |
| Alkermes PLC | 3.17% |
| Insmed Incorporated | 3.15% |
| Genmab A/S (ADR) | 3.13% |
| BioMarin Pharmaceutical, Inc. | 3.09% |
| Amgen, Inc. | 3.06% |
| Incyte Corporation | 3.00% |
| BeiGene Ltd. (ADR) | 2.95% |
| Total Net Asset Value of the Underlying Fund (in U | (SD) \$1,170,042,129 |

Commissions, management fees and expenses all may be associated with ETF investments. Please carefully read the simplified prospectus of the ETF before investing. ETFs are not guaranteed, their values change frequently and past performance may not be repeated. Data is as of March 31, 2024 (unaudited).

^{*}The First Trust ETF obtains exposure to the performance of an index of U.S. companies in the biotechnology industry, initially the NYSE® Arca Biotechnology Index (the "Index") by investing in the Underlying Fund, a U.S.-listed index fund (i.e. First Trust NYSE® Arca® Biotechnology Index Fund [the "Underlying Fund"]) which itself replicates or substantially replicates the Index.